#USA #Orlando #Leukemia #OncoPrecision #ONC001

OncoPrecision's Game-Changing Approach to Monocytic Leukemia Treatment

OncoPrecision Corporation, a pioneering player in cancer therapeutics, has announced a significant development in their fight against monocytic leukemia. The company revealed that its candidate, ONC001, which uniquely targets the CD64 receptor, will be presented orally at the forthcoming 67th American Society of Hematology (ASH) Annual Meeting, scheduled from December 6-9, 2025, in the vibrant city of Orlando, Florida.

What is ONC001?

ONC001 is a first-in-class antibody-drug conjugate (ADC) specifically designed to target CD64, a receptor that is primarily present in chronic myelomonocytic leukemia (CMML) and certain types of acute myeloid leukemia (AML). These cancers are often resistant to conventional treatments, posing a significant challenge for healthcare practitioners. The design of ONC001 aims to mitigate this resistance and provide a new avenue for patients suffering from these aggressive forms of leukemia.

The development process for ONC001 is quite innovative, utilizing a proprietary discovery engine by OncoPrecision that blends large-scale, patient-derived biological data with advanced artificial intelligence for high-throughput screening. This thorough approach allowed the researchers to uncover valuable cellular vulnerabilities, guiding them towards the identification of a high-affinity lead antibody that targets CD64, with the best ADC payload and linker chemistry designed to minimize unintended harm to healthy cells.

Upcoming Presentation Highlights

Dr. Gastón Soria, Co-Founder and Chief Scientific Officer of OncoPrecision, will present crucial data on ONC001 that includes:

• - Selective Engagement: Demonstrating how ONC001 effectively targets patient-derived CMML and AML cells.
• - Robust Activity: Showcasing the drug's performance in samples that are resistant to existing standard therapies.
• - In Vivo Efficacy: Presenting compelling results from animal models that substantiate ONC001's effectiveness across various treatment scenarios.

Tarek Zaki, the CEO and Co-Founder of OncoPrecision, expresses pride in receiving a slot for an oral presentation at this renowned conference. He emphasizes, “ONC001 is crafted to specifically counteract the resistance mechanisms that plague several aggressive blood cancers, marking it as a potential game-changer for patients who frequently experience treatment failures.”

The ASH Presentation Details

The oral presentation will take place as follows:

• - Title: ONC001: A first-in-class ADC targeting CD64 for the treatment of monocytic leukemia developed through patient-guided target and payload selection.
• - Presenter: Dr. Gastón Soria, PhD.
• - Session: 604. Molecular Pharmacology and Drug Resistance with specific focus on Myeloid Neoplasms.
• - Date: Saturday, December 6, 2025.
• - Time: 4:00 PM – 5:30 PM (presentation from 5:15 PM – 5:30 PM).
• - Venue: OCCC – Valencia Room W415D.

About OncoPrecision

OncoPrecision is at the forefront of oncology innovation, dedicated to developing precision medicines with a high likelihood of clinical success. The company’s unique approach integrates translational biology, machine learning, and advanced ADC engineering, positioning it for significant contributions to managing hematologic malignancies and solid tumors. OncoPrecision is actively pursuing strategic partnerships to expedite the progress and commercialization of its research initiatives.

The unveiling of ONC001 at the ASH Annual Meeting marks a crucial step forward in the ongoing battle against resistant cancers, and the global hematology community eagerly awaits this presentation to explore this promising therapeutic option's potential

In a fast-evolving field where resistance to treatment is a frequent occurrence, OncoPrecision’s ONC001 represents hope for patients who have few options left. As the medical community gathers in Orlando, the anticipation builds for what may be a pivotal development in leukemia treatment.